Frontlight ResearchEarly access
CompletedNo phase
SafeBoosC III Two-year Follow-up
Key facts
- Who runs it
- Gorm Greisen
- Where
- Denmark1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 1,601 people enrolled
- Started
- 23 Sept 2021
- Ended
- 19 Oct 2024
- Type of study
- Observational
- Treatments tested
- Treatment as usual + cerebral oximetry monitoring the first 72 hours of life
- Record updated
- 7 November 2024
Who can take part
- Age
- 12 months to 30 months
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 2 criteriaShow less
Who can take part
- Participation in the SafeBoosC-III trial and enrollment in a neonatal intensive care unit (NICU) taking part in the follow-up study, with parental consent according to local regulations
Who cannot take part
- Parental objection to the use of their child's data in the follow-up study
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The SafeBoosC-III 2 year follow up study will follow up on all patients randomised in the SafeBoosC-III clinical trial (NCT03770741). The investigators will collect data when the patients are two years of corrected age from routine standardised follow up assessments, parental questionnaires as well as informal assessments. The study will commence in September 2021, and will expect to include all 72 sites across 18 countries, which take part of the SafeBoosC-III clinical trial.
Treatments tested
- Treatment as usual + cerebral oximetry monitoring the first 72 hours of life
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Cerebral Near-infrared Spectroscopy Monitoring Versus Treatment as Usual for Extremely Preterm Infants: a Protocol for the Follow-up Study for the SafeBoosC-III Trial
- Record updated
- 7 November 2024